

Mangalam Drugs and Organics Ltd.



Regd. Office: Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413

09th May, 2019

To,

Corporate Relation Department
BSE Ltd
1st Floor, New Trade Wing,
Rotunda Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

National Stock Exchange of India
Limited
“Exchange Plaza”, C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 05

Scrip Code: 532637

Symbol: MANGALAM

Sub: Audited Financial Results for the Quarter and year ended on 31st March, 2019

Dear Sir,

In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith Audited Financial Results for the quarter and year ended 31st March, 2019 along with Auditors Report and the statement of Assets and Liabilities as at the year ended on March 31, 2019 in the prescribed format which have been taken on record and approved by the Board of Directors of the company in its meeting held today i.e. 09th May, 2019 at Mumbai.


Kindly note that meeting of Board of Directors commenced at 4.00 P.M. and concluded at 5.35 P.M.

Further please note that the company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations.

Kindly acknowledge the receipt and take the same on your records.

Thanking You,
Yours faithfully,
For Mangalam Drugs & Organics Ltd

Nikita Bavishi
Company Secretary



Audited Financial Results for the Quarter & Year Ended 31st March 2019 approved and taken on record by the Board at their meeting dated 09th May, 2019

Sr.No	Particulars	(Rs. In Lacs)				
		Quarter Ended			Year Ended	
		31.03.2019 Audited	31.12.2018 Unaudited	31.03.2018 Audited	31.03.2019 Audited	31.03.2018 Audited
A) Part-1 Statement of Audited Financial Results for the Quarter and Year Ended March 31, 2019						
1	Revenue from Operations	4,808.91	4,858.28	6,719.50	22,757.97	27,937.96
2	Other Income	20.53	4.54	10.26	31.68	82.70
3	Total Revenue(1+2)	4,829.44	4,862.82	6,729.76	22,789.65	28,020.66
4	Expenses					
	(a) Cost of Materials Consumed	3,737.07	3,951.23	4,044.52	16,870.28	18,047.91
	(b) Purchase of Stock in trade	0.00	0.00	0.00	0.00	0.00
	(c) Changes in Inventories, Finished Goods and Stock-in-trade	(181.73)	(784.01)	18.76	(1,538.93)	(1,711.73)
	(d) Employee Benefits Expenses	648.00	636.77	597.12	2,581.65	2,298.37
	(e) Finance Costs	252.54	229.53	342.92	864.65	1,178.00
	(f) Depreciation	165.70	183.49	257.78	708.85	656.82
	(fg) Other Expenses	579.19	1,153.61	1,107.97	3,876.85	4,616.57
	Total Expenses	5,200.78	5,370.62	6,369.07	23,363.35	25,085.94
5	Profit / (Loss) before exceptional & extraordinary items and tax(3-4)	(371.34)	(507.80)	360.69	(573.71)	2,934.72
6	Exceptional items	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before extraordinary items and tax (5-6)	(371.34)	(507.80)	360.69	(573.71)	2,934.72
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss (-) before tax(7-8)	(371.34)	(507.80)	360.69	(573.71)	2,934.72
10	Tax Expenses					
	Current Tax	0.00	(65.82)	55.15	0.00	659.63
	Deferred Tax	229.38	0.00	0.00	229.38	286.13
11	Net Profit(+)/Loss(-) after Tax (9-10)	(600.72)	(441.98)	305.54	(803.09)	1,988.96
12	Other Comprehensive income not reclassified into Profit & loss account (Net of Taxes)	0.43	0.41	(34.72)	1.69	36.32
13	Total Comprehensive Income	(600.29)	(441.57)	270.82	(801.40)	2,025.28
14	Paid-up Equity Share Capital (face value of Rs 10/- each)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
15	Other Equity					
16	Earnings Per Share (EPS) (of Rs 10/-each)not annualised):					
	(a) Basic	(3.80)	(2.79)	1.93	(5.07)	12.57
	(b) Diluted	(3.80)	(2.79)	1.93	(5.07)	12.57

Notes :

- The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read together with Companies (Indian Accounting Standard) Rules, 2015.
- The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on May 9, 2019. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
- As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
- Figures for the quarters ended 31st March 2019 and 31st March 2018 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures upto the third quarter of the respective financial years.
- The company has incurred loss during the year due to certain unforeseen circumstances & the major reason being delay in finalisation of tenders for malaria drugs by international regulatory. However we are confident of improved results in subsequent quarters once these procurements are streamlined by them shortly.
- Earlier period figures have been regrouped/ rearranged wherever necessary.

Place: Mumbai
Date: 09th May, 2019

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)




Statement of Assets and Liabilities		
	Rs. in Lacs	Rs. in Lacs
	As at 31.03.2019 Audited	As at 31.03.2018 Audited
ASSETS		
A. Non-current Assets		
(a) Property, Plant and Equipment	10077.78	10115.60
(b) Capital Work-In-Progress	19.95	7.13
(c) Intangible assets	48.52	75.31
(d) Financial Assets		
(i) Investments	24.01	24.01
(ii) Other Financial Assets	178.37	172.53
(iii) Deferred Tax Asset (Net)		
(e) Non Current Tax Assets (Net)		
(f) Other Non-current Assets	60.01	0.00
Total Non-current Assets (A)	10408.65	10,394.58
B. Current Assets		
(a) Inventories	7345.32	6013.42
(b) Financial Assets		
(i) Trade Receivables	1763.07	4520.77
(ii) Cash and Cash Equivalents	143.34	43.03
(iii) Bank Balance other than Cash and Cash Equivalents		
(iv) Loans	0.88	1.25
(v) Others Financial Assets		
(c) Other Current Assets	1251.36	1705.69
Total Current Assets (B)	10503.97	12,284.17
TOTAL ASSETS	20912.61	22,678.74
EQUITY AND LIABILITIES		
A. Equity		
(a) Equity Share Capital	1582.82	1582.82
(b) Other Equity	7992.80	8793.83
Total Equity (A)	9575.62	10,376.66
B. Non-Current Liability		
(a) Financial Liabilities		
(i) Borrowings	859.56	1114.64
(b) Deferred Tax Liabilities (Net)	1433.26	1202.98
(c) Provisions		
(d) Other Non-Current Liabilities		
Total Non-current Liabilities (B)	2292.82	2,317.63
C. Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	5051.20	5075.19
(ii) Trade Payables	3241.35	3762.51
(iii) Other Financial Liabilities	378.93	703.08
(b) Other Current Liabilities	313.59	372.82
(c) Provisions	59.10	70.87
Total Current Liabilities (C)	9044.17	9,984.46
TOTAL EQUITY AND LIABILITIES	20912.61	22,678.74

Notes:- 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

Place: Mumbai
Date: 09th May, 2019

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M. Dhoot)
Chairman & Managing Director
(DIN:01240086)



Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

TO THE BOARD OF DIRECTORS OF
MANGALAM DRUGS & ORGANICS LIMITED

We have audited the quarterly financial results of **MANGALAM DRUGS & ORGANICS LIMITED** for the quarter ended 31st March 2019 and the year to date results for the period 01st April 2018 to 31st March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- ii) give a true and fair view of the net loss and other financial information for the quarter ended 31st March 2019 and the year to date results for the period 01st April 2018 to 31st March 2019.

For Batliboi & Purohit
Chartered Accountants
FRN: 101048W


Raman Hangekar
Partner
M.No.:030615

Place: Mumbai
Date: 09th May 2019



BRANCHES :

NAVI MUMBAI : 302 / 304 Arenja Corner, Sector 17, Vashi, Navi Mumbai - 400 703. • Tel. : +91-22-2766 6478
DELHI : 505, Nirmal Tower, 26, Barakhamba Road, New Delhi -110 001. • Tel. : +91-11-4019 0200

Mangalam Drugs and Organics Ltd.

Regd. Office: Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



09th May, 2019

To,
Corporate Relation Department
BSE Ltd
1st Floor, New Trade Wing,
Rotunda Building, Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

National Stock Exchange of India
Limited
“Exchange Plaza”, C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 05

Scrip Code: 532637

Symbol: MANGALAM

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements), (Amendment) Regulations, 2016 w.r.t Audit Report with unmodified opinion.

Dear Sir/Madam,

I, Shri Govardhan M Dhoot – Managing Director of Mangalam Drugs & Organics Ltd (CIN: L24230MH1972PLC116413) having its Registered office at Rupam Building, 3rd Floor, 239, P.D'Mello Road, Near GPO, Mumbai- 400001, hereby declare that the Statutory Auditors of the Company i.e. Batliboi & Purohit, Chartered Accountants (Firm Registration No. 101048W) have issued an Audit Report with unmodified opinions on Standalone Annual Audited Financial Results for the Year ended 31st March, 2019.

This declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.


Govardhan M. Dhoot
Managing Director
DIN: 01240086

